Highnoon Laboratories Ltd
Public listed pharmaceutical manufacturer · Lahore · Pakistan
Publicly listed Lahore pharmaceutical manufacturer with a broad therapeutic portfolio, research and development operations and national distribution.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Highnoon Laboratories Limited
- Company type
- Public listed pharmaceutical manufacturer
- Address
- 17.5 KM, Multan Road, Lahore 53700, Pakistan · 53700
- Website
- highnoon-labs.com ↗
- Phone
- +92 42 111 000 465
- info@highnoon.com.pk
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| 5-FU | Fluorouracil (5-FU) | 500 mg | Injection | 10 Amp. | 016174 | PKR 4,409.30 | — | No comparator |
| 5-FU | Fluorouracil (5-FU) | 250 mg | Injection | 10 amp | 016175 | PKR 1,934.07 | PKR 193.41/vial/unit | No comparator |
| Alkyloxan | Cyclophosphamide | 200 mg | Injection | 50 | 016167 | PKR 694.78 | — | No comparator |
| Alkyloxan | Cyclophosphamide | 200 mg | Injection | 10 amp | 016168 | PKR 565.18 | PKR 56.52/vial/unit | No comparator |
| Amonate | Artesunate + Amodiaquine | 25 mg + 67.5 mg | Tablet | 20's | 062772 | PKR 93.08 | PKR 4.65/tablet | 6% below median |
| Amonate | Artesunate + Amodiaquine | 25 mg + 67.5 mg | Tablet | 3 | 062772 | PKR 27.22 | PKR 9.07/tablet | 88% above median |
| Amonate | Artesunate + Amodiaquine | 25 mg + 67.5 mg | Tablet | 6's | 062772 | PKR 30.31 | PKR 5.05/tablet | Near median |
| Amonate | Artesunate + Amodiaquine | 25 mg + 67.5 mg | Tablet | 10's | 062772 | PKR 48.71 | PKR 4.87/tablet | Near median |
| Amonate | Artesunate + Amodiaquine | 25 mg + 67.5 mg | Tablet | 12's | 062772 | PKR 57.36 | PKR 4.78/tablet | Near median |
| Amonate | Artesunate + Amodiaquine | 50 mg + 135 mg | Tablet | 3 | 062773 | PKR 44.72 | PKR 14.91/tablet | 6% below median |
| Amonate | Artesunate + Amodiaquine | 100 mg + 270 mg | Tablet | 20's | 062774 | PKR 259.76 | PKR 12.99/tablet | 33% below median |
| Amonate | Artesunate + Amodiaquine | 100 mg + 270 mg | Tablet | 6 | 062774 | PKR 151.65 | PKR 25.28/tablet | 90% above median |
| Amonate | Artesunate + Amodiaquine | 100 mg + 270 mg | Tablet | 10's | 062774 | PKR 133.13 | PKR 13.31/tablet | 31% below median |
| Amonate | Artesunate + Amodiaquine | 100 mg + 270 mg | Tablet | 12's | 062774 | PKR 160.19 | PKR 13.35/tablet | 31% below median |
| Apiban | Apixaban | 2.5 mg | Tablet | 30 | 104681 | PKR 3,522.09 | PKR 117.40/tablet | Near median |
| Apiban | Apixaban | 5 mg | Tablet | 30 | 104682 | PKR 3,744.19 | PKR 124.81/tablet | Near median |
| Artecxin | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16 | 047978 | PKR 622.15 | PKR 38.88/tablet | Near median |
| Artecxin | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 8 | 052596 | PKR 526.32 | PKR 65.79/tablet | Near median |
| Artecxin | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16 | 062802 | PKR 660.91 | PKR 41.31/tablet | 5% above median |
| Artecxin | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 8 | 062803 | PKR 570.82 | PKR 71.35/tablet | 11% above median |
| Artecxin plus | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6 | 067820 | PKR 508.38 | PKR 84.73/tablet | 22% below median |
| Artecxin plus | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 16 | 067820 | PKR 1,355.70 | PKR 84.73/tablet | 22% below median |
| Asthavent 100 | Salbutamol | 100 mcg | HFA inhaler | 1 | 072583 | PKR 413.07 | — | No comparator |
| Asthavent 100 | Salbutamol | 100 mcg | Metered-dose inhaler | 1 | 072583 | PKR 413.07 | — | No comparator |
| Benzisox | Risperidone | 1 mg | Tablet | 20 | 027653 | PKR 566.65 | PKR 28.33/tablet | 22% above median |
| Benzisox | Risperidone | 2 mg | Tablet | 20 | 027654 | PKR 1,107.56 | PKR 55.38/tablet | 51% above median |
| Benzisox | Risperidone | 3 mg | Tablet | 20 | 027655 | PKR 1,643.02 | PKR 82.15/tablet | 41% above median |
| Benzisox | Risperidone | 4 mg | Tablet | 20 | 027656 | PKR 2,101.94 | PKR 105.10/tablet | 45% above median |
| Breavent | Salbutamol | 200 mcg | Inhalation capsule | 30 | 044593 | PKR 139.55 | PKR 4.65/capsule | 85% above median |
| Budeform 100 | Budesonide | 100 mcg | HFA inhaler | 1 | 072588 | PKR 1,002.97 | — | No comparator |
| Budeform 100 | Budesonide | 100 mcg | Metered-dose inhaler | 1 | 072588 | PKR 1,002.97 | — | No comparator |
| Budeform 200 | Budesonide | 200 mcg | HFA inhaler | 1 | 072589 | PKR 1,367.30 | — | No comparator |
| Budeform 200 | Budesonide | 200 mcg | Metered-dose inhaler | 1 | 072589 | PKR 1,367.30 | — | No comparator |
| Budevair | Budesonide | 200 mcg | Inhalation capsule | 30 | 054312 | PKR 289.08 | PKR 9.64/capsule | Near median |
| Budevair | Budesonide | 100 mcg | Inhalation capsule | 30 | 054313 | PKR 207.34 | PKR 6.91/capsule | Near median |
| Budevair | Budesonide | 400 mcg | Inhalation capsule | 30 | 054318 | PKR 362.84 | PKR 12.09/capsule | 46% below median |
| Cisplatin | Cisplatin | 10 mg | Injection | 1 vial | 016170 | PKR 2,346.52 | PKR 2,346.52/vial/unit | Near median |
| Cisplatin Injection | Cisplatin | 10 mg | Injection | 1 vial | 016170 | PKR 2,346.52 | PKR 2,346.52/vial/unit | Near median |
| Cisplatin Injection | Cisplatin | 50 mg | Injection | 1 | 016171 | PKR 3,929.73 | — | No comparator |
| Combivair | Budesonide + Formoterol | 100 mcg + 6 mcg | Inhalation capsule | 30 | 054311 | PKR 425.95 | PKR 14.20/capsule | 7% above median |
| Combivair | Budesonide + Formoterol | 6 mcg + 100 mcg | Inhalation capsule | 60's | 054311 | PKR 834.87 | PKR 13.91/capsule | Near median |
| Combivair | Budesonide + Formoterol | 6 mcg + 100 mcg | Inhalation capsule | 40's | 054311 | PKR 556.59 | PKR 13.91/capsule | Near median |
| Combivair | Budesonide + Formoterol | 6 mcg + 100 mcg | Inhalation capsule | 50's | 054311 | PKR 695.74 | PKR 13.91/capsule | Near median |
| Combivair | Budesonide + Formoterol | 200 mcg + 6 mcg | Inhalation capsule | 60 | 054316 | PKR 1,169.66 | PKR 19.49/capsule | 6% above median |
| Combivair | Budesonide + Formoterol | 6 mcg + 200 mcg | Inhalation capsule | 50's | 054316 | PKR 974.71 | PKR 19.49/capsule | Near median |
| Combivair | Budesonide + Formoterol | 200 mcg + 6 mcg | Inhalation capsule | 30 | 054316 | PKR 596.77 | PKR 19.89/capsule | 8% above median |
| Combivair | Budesonide + Formoterol | 6 mcg + 200 mcg | Inhalation capsule | 40's | 054316 | PKR 779.77 | PKR 19.49/capsule | Near median |
| Combivair | Budesonide + Formoterol | 400 mcg + 6 mcg | Inhalation capsule | 30 | 054317 | PKR 681.09 | PKR 22.70/capsule | No comparator |
| Combivair | Budesonide + Formoterol | 6 mcg + 400 mcg | Inhalation capsule | 50's | 054317 | PKR 1,112.45 | PKR 22.25/capsule | Near median |
| Combivair | Budesonide + Formoterol | 6 mcg + 400 mcg | Inhalation capsule | 60 | 054317 | PKR 1,334.95 | PKR 22.25/capsule | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.